Table 4.
Comparison of PBPK model predicted and reported PK parameters of bevacizumab.
| Dose [mg/kg] | PK Parameters | Reported values from literaturea) | Predicted (PBPK) (13 years, with growth) |
|---|---|---|---|
| 15 | AUC0-inf [µg/ml*days] | 3180 ± 1655 | 4894 |
| (1.54)# | |||
| 15 | T1/2 [days] (2 weeks) | 9.6 ± 4.4 | 19.7 |
| (2.05)# | |||
| 15 | Vss [ml/kg] | 66.2 ± 15 | 77.6 |
| (1.17)# | |||
| 5 | AUC0-inf [µg/ml*days] | 1115 ± 264 | 1,475 |
| (1.32)# | |||
| 5 | T1/2 [days] (2 weeks) | 11.9 ± 1.7 | 18.5 |
| (1.55)# | |||
| 5 | Vss [ml/kg] | 73.7 ± 8.3 | 71.7 |
| (0.97)# |
a)Mean values and standard deviation. Age range of patients included in the study was 1–21 years, median age, 13 years (Glade Bender et al., 2008); # in brackets: ratio predicted/reported.